title: Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leonés (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.
abstract: In this study the incidence of DNA aneuploidy in a large series of untreated multiple myeloma (MM) patients was assessed in order to determine its clinical and prognostic significance. A total of 156 MM patients were included in the study. DNA measurements were performed in all cases at diagnosis using two different flow cytometry methods: (1) propidium iodide (PI) staining on isolated nuclei, and (2) CD38/PI double staining on whole cells. The DNA ploidy status was correlated with the most relevant clinical and haematological disease characteristics. From the 156 cases analysed, 91 (58%) were aneuploid (56% hyperdiploid and 2% hypodiploid). The correlation between the two techniques on the detection of DNA aneuploidy was excellent, although CD38/PI double staining would be preferable in cases with < 5% of DNA aneuploid plasma cells (PC). Upon comparing the clinical and haematological disease characteristics of hyperdiploid versus diploid cases, the former group was characterized by a lower age, reduced incidence of anaemia, lower beta 2M levels, higher proliferative activity within the residual normal haemopoietic cells, increased expression of CD56 antigen in PC, and higher proportion of PB CD4+ T cells. In contrast, diploid cases had a higher expression of the CD10, CD20 and CD15 antigens and greater numbers of PB CD56+CD3- NK cells (P < 0.05). Circulating PC were identified in six cases, all being diploid. Overall survival was significantly longer in hyperdiploid compared to diploid MM (P = 0.02). These results show that over 50% of MM patients are aneuploid, almost all of them being hyperdiploid. This characteristic is associated with better prognosis.
authors.affiliation: Department of Haematology, University Hospital of Salamanca, University of Salamanca, Spain.
authors.forename: R
authors.initials: R
authors.lastname: García-Sanz
authors.forename: A
authors.initials: A
authors.lastname: Orfão
authors.forename: M
authors.initials: M
authors.lastname: González
authors.forename: M J
authors.initials: MJ
authors.lastname: Moro
authors.forename: J M
authors.initials: JM
authors.lastname: Hernández
authors.forename: F
authors.initials: F
authors.lastname: Ortega
authors.forename: D
authors.initials: D
authors.lastname: Borrego
authors.forename: M
authors.initials: M
authors.lastname: Carnero
authors.forename: F
authors.initials: F
authors.lastname: Casanova
authors.forename: R
authors.initials: R
authors.lastname: Jiménez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000782:Aneuploidy; D002453:Cell Cycle; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D016130:Immunophenotyping; D016131:Lymphocyte Subsets; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000235:genetics* / Q000276:immunology; D011379:Prognosis; D015996:Survival Rate; D001613:beta 2-Microglobulin / Q000032:analysis
chemical_list: D004273:DNA, Neoplasm; D001613:beta 2-Microglobulin